Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring sold 8,148 shares of common stock in an open-market transaction on March 2, 2026. The shares were sold at a weighted average price of $15.4385 per share under a previously adopted Rule 10b5-1 trading plan. Following this sale, she directly holds 34,601 Nurix shares.
Christine Ring reported a Form 144 covering 8,148 common shares issuable from Restricted Stock Units dated 05/02/2022, to be sold through Morgan Stanley Smith Barney LLC. The filing lists multiple recent 10b5-1 sales by Ms. Ring on 12/18/2025, 01/20/2026, and 02/09/2026, with per-trade proceeds shown.
Nurix Therapeutics, Inc. is the subject of an amended Schedule 13G filing by Baker Bros. entities reporting a significant ownership position. The reporting group discloses beneficial ownership of 7,527,996 shares of Nurix common stock, representing 7.2% of the class, as of an outstanding share count of 101,807,484 shares on November 30, 2025.
The position includes 4,658,556 shares of common stock plus 2,869,440 additional shares issuable upon exercise of pre-funded warrants with a $0.001 exercise price. These pre-funded warrants are generally limited by a 9.99% beneficial ownership cap, which the funds may adjust up to 19.99% effective on the 61st day after written notice to the issuer.
Within the Baker Bros. complex, 667, L.P. holds 393,250 shares and 248,551 warrant shares, while Baker Brothers Life Sciences, L.P. holds 4,265,306 shares and 2,620,889 warrant shares, all subject to the ownership cap. Baker Bros. Advisors LP exercises investment and voting discretion for the funds and is reporting on a passive, non-control basis under Schedule 13G.
Nurix Therapeutics Chief Financial Officer Hans van Houte received new equity awards in the form of stock options and restricted stock units. On February 10, 2026, he was granted an employee stock option for 93,750 shares of common stock at an exercise price of $16.45 per share, vesting in equal monthly installments over three years until February 9, 2029, while he continues serving the company.
He was also granted 42,875 restricted stock units, each representing one share of common stock. These RSUs vest in equal quarterly installments over three years, with the first portion vesting on July 30, 2026, contingent on his continued service; vested shares will be delivered after each vesting date.
Nurix Therapeutics Chief Legal Officer receives new equity awards. On February 10, 2026, Christine Ring was granted an employee stock option for 93,750 shares of common stock at an exercise price of $16.45 per share and 42,875 restricted stock units.
The stock option vests in equal monthly installments over 36 months beginning March 10, 2026, and is fully vested by February 9, 2029, contingent on continued service. The RSUs vest in 12 quarterly installments over three years starting July 30, 2026, with one share of common stock delivered for each vested unit.
Nurix Therapeutics, Inc. reported that Chief Scientific Officer Gwenn Hansen received new equity awards on February 10, 2026. She was granted an option to buy 93,750 shares of common stock at $16.45 per share, vesting monthly over three years through February 9, 2029, subject to continued service.
Hansen was also granted 42,875 restricted stock units, each representing one share of common stock. These RSUs vest in 12 equal quarterly installments over three years, beginning July 30, 2026, with shares delivered after each vesting date as long as she remains in service.
Nurix Therapeutics President and CEO Arthur T. Sands received an employee stock option grant covering 562,500 shares of common stock at an exercise price of $16.45 per share on February 10, 2026.
The option vests in 36 equal monthly installments beginning March 10, 2026, and becomes fully vested on February 9, 2029, subject to his continued service. It is scheduled to expire on February 9, 2036.
Nurix Therapeutics’ Chief Legal Officer, Christine Ring, reported a planned sale of company stock. On 02/09/2026 she sold 14,261 shares of Nurix common stock at a weighted average price of $16.6621 per share under a pre‑arranged Rule 10b5‑1 trading plan. Following this sale, she beneficially owns 42,749 shares of Nurix common stock directly.
A shareholder of NRIX has filed a Rule 144 notice to sell 14,261 common shares, with an aggregate market value of $240,297.85, through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 02/09/2026.
The shares were acquired as restricted stock units from the issuer on 05/02/2022. The filing also notes prior sales under a Rule 10b5-1 plan, including 3,760 shares sold on 01/20/2026 for $69,273.11 and 37,600 shares sold on 11/24/2025 for $641,697.02. Shares outstanding were 102,843,012 at the time referenced.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported an option exercise and corresponding stock acquisition. On 02/03/2026, Hansen exercised an employee stock option for 31,333 shares of common stock at $0.84 per share, converting the derivative position to common stock. Following this transaction, Hansen directly beneficially owns 115,005 shares of Nurix common stock, and the reported option grant is fully vested with 0 derivative securities remaining.